SOURCE: Insulet Corporation

Insulet Corporation

June 05, 2015 08:00 ET

Insulet Corporation Celebrates a Decade of Innovation at the American Diabetes Association's 75th Scientific Sessions

Tubeless Insulin Pump Manufacturer to Showcase 10-Year History of the OmniPod and Recent Partnerships; Company to Host Panel Discussion on the Artificial Pancreas Project

BILLERICA, MA--(Marketwired - Jun 5, 2015) - Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, will celebrate the 10-year anniversary of the OmniPod at the American Diabetes Association's 75th Annual Scientific Sessions in Boston with a showcase of its advanced technology and commitment to building partnerships in the diabetes space. Insulet will feature interactive demonstrations of the latest diabetes technology platforms offered with the OmniPod System and also host an offsite panel discussion highlighting the history of the Artificial Pancreas Project and the impact of future diabetes innovations.

Insulet will showcase the company's commitment to innovation through partnerships with DexCom, as well as two innovative companies in the data management space, Tidepool and Glooko, at booth 1516. Insulet is partnering with DexCom to develop a device that will allow information from DexCom's 5th generation CGM system to be identified, received and displayed on Insulet's Bluetooth-enabled Personal Diabetes Manager (PDM), currently in development. These partnerships will provide patients and healthcare providers the opportunity to access data that will allow them to take full advantage of the clinical and lifestyle benefits of the tubeless OmniPod System. Insulet's booth will offer guests interactive demonstrations of these data management platforms with the OmniPod System. 

In celebration of the 10th anniversary of the OmniPod, Insulet will also present a unique view into the history of the OmniPod and the opportunity to experience the newest generation technology firsthand by trying on the OmniPod at booth 1405. Booth visitors will have a chance to run through an advanced features training, participate in physician-focused market research around a new PDM scheduled to come out next year and experience the "Try It On" area where participants can wear a demo OmniPod. For each OmniPod a booth guest tries on, Insulet will make a $7.50 donation to the American Diabetes Association to celebrate their 75th anniversary.

Furthering its dedication to innovation, Insulet will host an offsite healthcare provider event, Journey to the Artificial Pancreas. Insulet's Medical Director, Howard Zisser, MD, will moderate a panel featuring Frank Doyle, the newly appointed Dean of the School of Engineering and Applied Sciences at Harvard University, Dr. med. Guido Freckmann from the Institute of Diabetes-Technology at the University of Ulm in Germany, and Jen Blume, a patient from the UC Santa Barbara/Sansum Artificial Pancreas Studies. The panel discussion will focus on the history of the Artificial Pancreas Project, the future of diabetes management and how research and innovation will work together to give patients better control of their diabetes.

"We are thrilled to be celebrating 10 years of OmniPod making diabetes a smaller part of life for thousands of people living with diabetes and their loved ones," said Patrick Sullivan, President and Chief Executive Officer. "Insulet's commitment to innovation will be on display at ADA with a presentation of OmniPod and demonstrations of the latest platforms incorporated into the technology. These platforms will help provide people affected by diabetes with enhanced tools to facilitate better blood sugar control. For many years the OmniPod has also been a significant part of the Artificial Pancreas Project. We are thrilled to have such an esteemed panel to discuss this important advancement in diabetes research. All of these developments help contribute to the overall mission of creating a healthier future for people living with diabetes and we are proud to support that effort."

About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor of diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D: Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit:

Contact Information

  • Investor Relations and Media Contact:
    Deborah R. Gordon
    Vice President, Investor Relations and Corporate Communications
    (978) 600-7717 or